Drugs / Keynatinib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04807881 | Sep 2020 → Oct 2027 expected | B-cell non-Hodgkin lymphoma | Medolution Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04824079 | Oct 2020 → Dec 2024 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Medolution Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Keynatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04824079 ↗ |